← Back to Clinical Trials
Recruiting NCT04364373

NCT04364373 D2 vs D3 Lymph Node Dissection for Left Colon Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04364373
Status Recruiting
Phase
Sponsor Russian Society of Colorectal Surgeons
Condition Colon Cancer
Study Type INTERVENTIONAL
Enrollment 1,381 participants
Start Date 2020-03-31
Primary Completion 2028-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
Left colon resectionSigmoid colon resectionDistal sigmoid colon resection or anterior resection

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 1,381 participants in total. It began in 2020-03-31 with a primary completion date of 2028-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The efficiency of the D3 lymph node dissection is still controversial for left colon cancer patients. This study will try find difference in 5-year overall survival between D2 and D3 lymph node dissection. Investigation of the functional and short-term outcomes will clarify safety of the D3 lymph node dissection.

Eligibility Criteria

Inclusion Criteria: 1. Agreement of the patient to participate in trial 2. Colon cancer (only adenocarcinoma ) 3. The tumor located between the splenic flexure and rectosigmoid junction 4. cT3-Т4а,b 5. cN0-2 6. cM0 7. Tolerance of chemotherapy 8. ASA 1-3 Exclusion Criteria: 1. сТis - Т2, сТ4b (tail of the pancreas, stomach, small bowel, ureter, urinary bladder) 2. Preoperative complications of the tumor (perforation and full bowel 3. obstruction) 3. Previous radiotherapy or chemotherapy 4. Synchronous or metachronous tumors 5. Women during Pregnancy or breast feeding period

Contact & Investigator

Central Contact

Vladimir Balaban, Ph.D

✉ balaban@kkmx.ru

📞 +79889478358

Principal Investigator

Peter Tsarkov, Ph.D

STUDY DIRECTOR

I.M. Sechenov First Moscow State Medical University

Frequently Asked Questions

Who can join the NCT04364373 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Colon Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04364373 currently recruiting?

Yes, NCT04364373 is actively recruiting participants. Contact the research team at balaban@kkmx.ru for enrollment information.

Where is the NCT04364373 trial being conducted?

This trial is being conducted at Moscow, Russia.

Who is sponsoring the NCT04364373 clinical trial?

NCT04364373 is sponsored by Russian Society of Colorectal Surgeons. The principal investigator is Peter Tsarkov, Ph.D at I.M. Sechenov First Moscow State Medical University. The trial plans to enroll 1,381 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology